Clinical Study
Tissue Factor Expression in Obese Type 2 Diabetic Subjects and Its Regulation by Antidiabetic Agents
Table 1
(a) Metabolic characteristics of subjects and (b) baseline parameters of subjects prior to treatment with metformin or rosiglitazone.
| (a) |
| | | ND | T2D |
| | (F/M) | 10 (2/8) | 13 (5/8) | | Age (years) | 45 ± 10.3 | 57 ± 9.5 | | BMI (kg/m2) | 35.6 ± 5.6 | 35.6 ± 7.1 | | Weight (kg) | 105 ± 17.3 | 101 ± 15.9 | | Fasting glucose (mmol/L) | 5.5 ± 0.7 | 7.7 ± 1.6* | | Fasting insulin (pmol/L) | 84 ± 23.0 | 148 ± 31* | | FFA (mmol/L) | 0.32 ± 0.18 | 0.66 ± 0.25* | | HbA1c (%) | 5.5 ± 0.6 | 7.2 ± 1.3* | | TG (mg/dl) | 132 ± 77 | 191 ± 90 |
|
|
| (b) |
| | | Metformin () | Rosiglitazone () |
| | BMI (kg/m2) | 35.45 ± 5.4 | 32.91 ± 6.3 | | Weight (Kg) | 103 ± 14.9 | 97.5 ± 18.9 | | Fasting glucose (mmol/L) | 7.4 ± 2.2 | 9.3 ± 2.4 | | Fasting insulin (pmol/L) | 140.6 ± 70.1 | 95.1 ± 39.5 | | FFA (mmol/L) | 0.484 ± 0.12 | 0.482 ± 0.142 | | HbA1c (%) | 6.48 ± 0.65 | 8.0 ± 1.2 | | TG (mg/dl) | 158 ± 49.6 | 142 ± 71 |
|
|
For Tables 1(a) and 1(b), data are means ± SD. TG, triglyceride.
Table 1(a): * < 0.05; ND versus T2D.
|
